Pharmaceutical Industry Outlook: Tariffs, Tech, and Global Supply Chains

Why Tariffs Have Pharma on Edge

Hi readers! Curious about what’s shaking up the pharmaceutical industry? Theres been a ton of tariff drama this year, so let’s talk about it and why it matters.

The U.S. pharmaceutical market is massive. North America accounts for more than half of global retail, hospital, and prescription sales. The U.S isn’t just a player; it’s a key link in the global supply chain, connecting manufacturing, packaging, and clinical development across continents. That’s why the recent tariff threats have everyone talking.

From October 1, branded or patented drugs imported into the U.S. were set to face 100% tariffs unless the manufacturer had U.S.-based facilities or construction underway. The plan is on pause for now, but uncertainty is real. If these tariffs go live, a ripple effect could reach far beyond U.S. borders.

Let’s break it down.

Tariffs and Supply Chain Risks

A 15% tariff would hurt. A 100% tariff? That’s a game-changer. Pharmaceutical supply chains are global by design. Active ingredients might come from India, packaging from Europe, and clinical trials from Asia. Disrupt that flow, and the entire system feels it.

Brady McKinney, Atradius Underwriter in Baltimore, explains in a recent report: “Heightened supply chain protectionism, particularly between the U.S. and Mainland China, would drive pharmaceutical companies to establish separate supply chains to mitigate risk. This would result in less efficiency in global pharma manufacturing networks.”

He adds that companies are already shifting from cost-focused strategies to risk-focused ones. Resilience is the new priority. Nearshoring to Latin America, Eastern Europe, Southeast Asia is gaining traction as a safer alternative to full reshoring.

How Tariffs Could Hit Prices and Patients

Branded drugs dominate spending, and they are severely in the tariff crossfire. A 100% tariff could mean higher cost for companies and consumers, plus pressure on supply chains that rely heavily on imported active pharmaceutical ingredients.

McKinney notes these challenges come as the industry faces patent expirations and pricing reforms. Tariffs could accelerate reshoring and nearshoring strategies, but these moves require major investment and may divert resources from innovation.

Since September 2025, major pharmaceutical companies like Eli Lilly, Novo Nordisk, AstraZeneca, Pfizer, and Merck have struck deals with the Trump administration under a “most favored nation” framework. Through TrumpRX, a proposed direct-to-consumer platform, these companies agreed to sell certain drugs and future medicines at lower prices. In return, they announced new U.S.-based investments in manufacturing and research and development.

The administration responded by granting a three-year grace period on Section 232 tariffs that would have applied to some products. This temporary relief buys time, but uncertainty remains.

Finally, there’s the GLP-1 boom. Drugs like Ozempic and Wegovy are fueling growth in diabetes and obesity treatment. They’re complex biologics with global supply chains, which makes them vulnerable to tariff shocks. If costs spike, access could suffer, and the ripple effect would be felt across healthcare systems.

AI’s role in Pharma

AI is transforming how pharma works. AI is helping companies discover new drugs faster, predict supply chain hiccups, and even cut waste in production. Algorithms can now scan millions of data points to find the next breakthrough drug in record time. It’s also making manufacturing greener by reducing energy use and improving efficiency. In short, smart tech is becoming a must have for staying competitive and sustainable.

What does this mean for Pharma’s Future?

Tariffs may sound technical, but they could reshape the U.S pharmaceutical industry. From supply chain challenges to rising costs, the impact is real. Big changes in supply chains, pricing, and access are coming, especially for high-demand treatments like GLP-1 drugs.

The good news? Companies are already adapting, exploring nearshoring, investing in resilience, and leaning on AI to stay ahead. One thing is certain, the industry is entering a new chapter, and flexibility will be key.

To go more in depth, check out our recent report on the pharmaceutical industry. How are US tariffs impacting the global pharmaceutical industry

Get the Latest Trends & Insights

Be the first to know about economic and political changes affecting you and your customers’ business, delivered right to your inbox.

Sign Up